Novel insights from genetic and epigenetic studies in understanding the complex uraemic phenotype

Nephrology Dialysis Transplantation

Volumn 29, Issue 5, 2014, Pages 964-971

  Witasp, Anna ^a   Ekström, Tomas J ^a   Lindholm, Bengt ^a   Stenvinkel, Peter ^a   Schalling, Martin ^a   Nordfors, Louise ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Chronic kidney disease; epigenetics; ethnicity; genetics; GWAS

Indexed keywords

DNA;

ADVERSE OUTCOME; AFRICAN AMERICAN; APOL1 GENE; ARTICLE; ASIAN; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DNA METHYLATION; EPIGENETICS; EPISTASIS; ETHNIC DIFFERENCE; GENE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC RISK; GENETIC VARIABILITY; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MULTIFACTORIAL INHERITANCE; MYH9 GENE; PATHOPHYSIOLOGY; PHENOTYPE; PLEIOTROPY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; UREMIA;

CHRONIC KIDNEY DISEASE; EPIGENETICS; ETHNICITY; GENETICS; GWAS;

DISEASE SUSCEPTIBILITY; EPIGENOMICS; GENETIC MARKERS; GENOME, HUMAN; GENOMICS; HUMANS; PHENOTYPE; RENAL INSUFFICIENCY, CHRONIC; UREMIA;

EID: 84899839607     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft428     Document Type: Article

References (74)

1. Witasp A, Nordfors L, Carrero JJ et al. Genetic studies in chronic kidney disease: interpretation and clinical applicability. J Nephrol 2012; 25: 851-864
2. Lander ES, Linton LM, Birren B et al. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921
3. Venter JC, Adams MD, Myers EW et al. The sequence of the human genome. Science 2001; 291: 1304-1351
4. A haplotype map of the human genome. Nature 2005; 437: 1299-1320
5. International HapMap C. The International HapMap Project. Nature 2003; 426: 789-796
6. Klein RJ, Zeiss C, Chew EY et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005; 308: 385-389
7. Hardy J, Singleton A. Genomewide association studies and human disease. N Engl J Med 2009; 360: 1759-1768
8. O'Seaghdha CM, Fox CS. Genome-wide association studies of chronic kidney disease: what have we learned? Nat Rev Nephrol 2012; 8: 89-99
9. Kottgen A, Glazer NL, Dehghan A et al. Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet 2009; 41: 712-717
10. Serafini-Cessi F, Malagolini N, Cavallone D. Tamm-Horsfall glycoprotein: biology and clinical relevance. Am J Kidney Dis 2003; 42: 658-676
11. Hart TC, Gorry MC, Hart PS et al. Mutations of the UMOD gene are responsible for medullary cystic kidney disease 2 and familial juvenile hy-peruricaemic nephropathy. J Med Genet 2002; 39: 882-892
12. Chambers JC, Zhang W, Lord GM et al. Genetic loci influencing kidney function and chronic kidney disease. Nat Genet 2010; 42: 373-375
13. Kottgen A, Pattaro C, Boger CA et al. New loci associated with kidney function and chronic kidney disease. Nat Genet 2010; 42: 376-384
14. Boger CA, Gorski M, Li M et al. Association of eGFR-related loci identified by GWAS with incident CKD and ESRD. PLoS Genet 2011; 7: e1002292
15. Ellis JW, Chen MH, Foster MC et al. Validated SNPs for eGFR and their associations with albuminuria. Hum Mol Genet 2012; 21: 3293-3298
16. Pattaro C, Kottgen A, Teumer A et al. Genome-wide association and functional follow-up reveals new loci for kidney function. PLoS Genet 2012; 8: e1002584
17. Pezzolesi MG, Poznik GD, Mychaleckyj JC et al. Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes. Diabetes 2009; 58: 1403-1410
18. Freedman BI, Langefeld CD, Lu L et al. Differential effects of MYH9 and APOL1 risk variants on FRMD3 association with diabetic ESRD in African Americans. PLoS Genet 2011; 7: e1002150
19. Hu C, Zhang R, Yu W et al. CPVL/CHN2 genetic variant is associated with diabetic retinopathy in Chinese type 2 diabetic patients. Diabetes 2011; 60: 3085-3089
20. Maeda S, Araki S, Babazono T et al. Replication study for the association between four loci identified by a genome-wide association study on European American subjects with type 1 diabetes and susceptibility to diabetic nephropathy in Japanese subjects with type 2 diabetes. Diabetes 2010; 59: 2075-2079
21. Shimazaki A, Kawamura Y, Kanazawa A et al. Genetic variations in the gene encoding ELMO1 are associated with susceptibility to diabetic ne-phropathy. Diabetes 2005; 54: 1171-1178
22. Leak TS, Perlegas PS, Smith SG et al. Variants in intron 13 of the ELMO1 gene are associated with diabetic nephropathy in African Americans. Ann Hum Genet 2009; 73: 152-159
23. Pezzolesi MG, Katavetin P, Kure M et al. Confirmation of genetic associations at ELMO1 in the GoKinD collection supports its role as a susceptibility gene in diabetic nephropathy. Diabetes 2009; 58: 2698-2702
24. Sandholm N, Salem RM, McKnight AJ et al. New susceptibility loci associated with kidney disease in type 1 diabetes. PLoS Genet 2012; 8: e1002921
25. Liu CT, Garnaas MK, Tin A et al. Genetic association for renal traits among participants of African ancestry reveals new loci for renal function. PLoS Genet 2011; 7: e1002264
26. Consortium HP-AS, Abdulla MA, Ahmed I et al. Mapping human genetic diversity in Asia. Science 2009; 326: 1541-1545
27. Okada Y, Sim X, Go MJ et al. Meta-analysis identifies multiple loci associated with kidney function-related traits in east Asian populations. Nat Genet 2012; 44: 904-909
28. Kiberd BA, Clase CM. Cumulative risk for developing end-stage renal disease in the US population. J Am Soc Nephrol 2002; 13: 1635-1644
29. Kao WH, Klag MJ, Meoni LA et al. MYH9 Is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 2008; 40: 1185-1192
30. Kopp JB, Smith MW, Nelson GW et al. MYH9 Is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008; 40: 1175-1184
31. Freedman BI, Hicks PJ, Bostrom MA et al. Non-muscle myosin heavy chain 9 gene MYH9 associations in African Americans with clinically diagnosed type 2 diabetes mellitus-associated ESRD. Nephrol Dial Transplant 2009; 24: 3366-3371
32. O'Seaghdha CM, Parekh RS, Hwang SJ et al. The MYH9/APOL1 region and chronic kidney disease in European-Americans. Hum Mol Genet 2011; 20: 2450-2456
33. Genovese G, Friedman DJ, Ross MD et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329: 841-845
34. Rosset S, Tzur S, Behar DM et al. The population genetics of chronic kidney disease: insights from the MYH9-APOL1 locus. Nat Rev Nephrol 2011; 7: 313-326
35. Tzur S, Rosset S, Shemer R et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 2010; 128: 345-350
36. Kathiresan S, Willer CJ, Peloso GM et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet 2009; 41: 56-65
37. Strawbridge RJ, Dupuis J, Prokopenko I et al. Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes. Diabetes 2011; 60: 2624-2634
38. Putter C, Pechlivanis S, Nothen MM et al. Missing heritability in the tails of quantitative traits? A simulation study on the impact of slightly altered true genetic models. Hum Hered 2011; 72: 173-181
39. Perry JR, Voight BF, Yengo L et al. Stratifying type 2 diabetes cases by BMI identifies genetic risk variants in LAMA1 and enrichment for risk variants in lean compared to obese cases. PLoS Genet 2012; 8: e1002741
40. Berndt SI, Gustafsson S, Magi R et al. Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet 2013; 45: 501-512
41. Tonelli M, Wiebe N, Culleton B et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006; 17: 2034-2047
42. Jager KJ, Stel VS, Zoccali C et al. The issue of studying the effect of interventions in renal replacement therapy-to what extent may we be deceived by selection and competing risk? Nephrol Dial Transplant 2010; 25: 3836-3839
43. Reich DE, Lander ES. On the allelic spectrum of human disease. Trends Genet 2001; 17: 502-510
44. Rivas MA, Beaudoin M, Gardet A et al. Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nat Genet 2011; 43: 1066-1073
45. Sulem P, Gudbjartsson DF, Walters GB et al. Identification of low-frequency variants associated with gout and serum uric acid levels. Nat Genet 2011; 43: 1127-1130
46. Kottgen A, Yang Q, Shimmin LC et al. Association of estimated glomerular filtration rate and urinary uromodulin concentrations with rare variants identified by UMOD gene region sequencing. PLoS One 2012; 7: e38311
47. Shea J, Agarwala V, Philippakis AA et al. Comparing strategies to fine-map the association of common SNPs at chromosome 9p21 with type 2 diabetes and myocardial infarction. Nat Genet 2011; 43: 801-805
48. Nejentsev S, Walker N, Riches D et al. Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes. Science 2009; 324: 387-389
49. Hunt KA, Mistry V, Bockett NA et al. Negligible impact of rare autoimmune-locus coding-region variants on missing heritability. Nature 2013; 498:232-235
50. Aitman TJ, Dong R, Vyse TJ et al. Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature 2006; 439: 851-855
51. Jin W, Qin P, Lou H et al. A systematic characterization of genes underlying both complex and Mendelian diseases. Hum Mol Genet 2012; 21: 1611-1624
52. Lander ES. Initial impact of the sequencing of the human genome. Nature 2011; 470: 187-197
53. 1000 Genomes A Deep Catalog of Human Genetic Variation. http://www.1000genomes.org/
54. DeJesus-Hernandez M, Mackenzie IR, Boeve BF et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011; 72: 245-256
55. Renton AE, Majounie E, Waite A et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011; 72: 257-268
56. Manolio TA, Collins FS, Cox NJ et al. Finding the missing heritability of complex diseases. Nature 2009; 461: 747-753
57. Sun L, Rommens JM, Corvol H et al. Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis. Nat Genet 2012; 44: 562-569
58. Schork AJ, Thompson WK, Pham P et al. All SNPs are not created equal: genome-wide association studies reveal a consistent pattern of enrichment among functionally annotated SNPs. PLoS Genet 2013; 9: e1003449
59. Chasman DI, Fuchsberger C, Pattaro C et al. Integration of genome-wide association studies with biological knowledge identifies six novel genes related to kidney function. Hum Mol Genet 2012; 21: 5329-5343
60. Andreassen OA, Thompson WK, Schork AJ et al. Improved detection of common variants associated with schizophrenia and bipolar disorder using pleiotropy-informed conditional false discovery rate. PLoS Genet 2013; 9: e1003455
61. Dwivedi RS, Herman JG, McCaffrey TA et al. Beyond genetics: epigenetic code in chronic kidney disease. Kidney Int 2011; 79: 23-32
62. Feinberg AP, Irizarry RA. Evolution in health and medicine Sackler colloquium: stochastic epigenetic variation as a driving force of development, evolutionary adaptation, and disease. Proc Natl Acad Sci USA 2010;107: 1757-1764
63. Egger G, Liang G, Aparicio A et al. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429: 457-463
64. Feinberg AP. Genome-scale approaches to the epigenetics of common human disease. Virchows Arch 2010; 456: 13-21
65. Geisel J, Schorr H, Heine GH et al. Decreased p66Shc promoter methyla-tion in patients with end-stage renal disease. Clin Chem Lab Med 2007; 45: 1764-1770
66. Ingrosso D, Cimmino A, Perna AF et al. Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocystei-naemia in patients with uraemia. Lancet 2003; 361: 1693-1699
67. Stenvinkel P, Karimi M, Johansson S et al. Impact of inflammation on epi-genetic DNA methylation-A novel risk factor for cardiovascular disease? J Intern Med 2007; 261: 488-499
68. Lund G, Andersson L, Lauria M et al. DNA Methylation polymorphisms precede any histological sign of atherosclerosis in mice lacking apolipo-protein E. J Biol Chem 2004; 279: 29147-29154
69. Zaina S, Lindholm MW, Lund G. Nutrition and aberrant DNA methyla-tion patterns in atherosclerosis: more than just hyperhomocysteinemia? J Nutr 2005; 135: 5-8
70. Valinluck V, Tsai HH, Rogstad DK et al. Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2). Nucleic Acids Res 2004; 32: 4100-4108
71. Sapienza C, Lee J, Powell J et al. DNA Methylation profiling identifies epi-genetic differences between diabetes patients with ESRD and diabetes patients without nephropathy. Epigenetics 2011; 6: 20-28
72. Zawada AM, Rogacev KS, Heine GH. Clinical relevance of epigenetic dys-regulation in chronic kidney disease-associated cardiovascular disease. Nephrol Dial Transplant 2013; 28: 1663-1671
73. Song CX, Szulwach KE, Fu Y et al. Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nat Biotechnol 2011; 29: 68-72
74. Valinluck V, Sowers LC. Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1. Cancer Res 2007; 67: 946-950